Experts Link GLP-1 Weight Loss Drugs to Potential Increase in Divorce Rates

GLP-1 receptor agonists, including Ozempic and Wegovy, have gained widespread use for weight management and diabetes control. Fox News reported that experts, drawing from data on bariatric surgery patients, suggest these drugs could lead to increased divorce rates. The pattern mirrors findings where surgery patients were twice as likely to divorce compared to the general population.

Per-Arne Svensson, a professor at the Institute of Health and Care Sciences in Sweden, has examined the relationship between weight loss and marital status. He noted that substantial weight loss, often occurring within the first year of treatment, may alter relationship dynamics. These changes could eventually lead to divorce proceedings.

“The effect likely unfolds in several stages," Svensson told Fox News Digital. "First, a substantial amount of weight must be lost, which typically occurs within the first year. " Studies from 2013 indicate that significant weight loss in one partner, while the other remains unchanged, can create tension.”

This may result from feelings of insecurity or criticism from the unchanged partner. Svensson explained that weight loss can enhance autonomy and confidence, potentially prompting individuals to end unhealthy relationships.

using GLP-1 drugs often experience shifts in lifestyle, including greater social engagement and attention from others.

Svensson stated that these changes, rather than alterations in temperament or brain chemistry, contribute to relationship strains. He added that single individuals may have a higher likelihood of forming new relationships after weight loss. Bariatric surgery typically results in greater average weight loss than current GLP-1 medications.

However, Svensson noted that as more effective drugs are developed, their impact on relationships could become comparable to surgery. GLP-1 drugs also aid in reducing habits like smoking and drinking, alongside their primary benefits.

address potential risks, Svensson recommends that couples approach weight loss collaboratively.

Involving both partners in lifestyle changes, such as diet and exercise, can foster a shared experience. He suggested that partners with clinical needs undertake treatment together to maintain relationship stability. The rising popularity of GLP-1 drugs highlights their role in public health for obesity and diabetes management.

Background on these medications includes FDA approvals for drugs like higher-dose Wegovy. Affected individuals include those using the drugs for weight loss, their partners, and healthcare providers monitoring long-term effects. Next steps may involve further research to confirm patterns in GLP-1 users, similar to bariatric studies.

Couples counseling or joint wellness programs could emerge as supportive measures. Ongoing studies continue to evaluate both metabolic benefits and social consequences of these treatments.